Recent Finacing
Recent Raise
Acer Therapeutics develops therapies for rare genetic diseases, advancing ACER-002 (celiprolol) for vascular Ehlers‑Danlos and ACER-001 (sodium phenylbutyrate) for MSUD and UCD toward NDAs and pivotal trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors